

# Looking back in time: conducting a cohort study of the long-term effects of treatment of adolescent tall girls with synthetic hormones

Fiona J Bruinsma\*<sup>1</sup>, Jo-Anne Rayner<sup>1</sup>, Alison J Venn<sup>2</sup>, Priscilla Pyett<sup>3</sup>, George Werther<sup>4</sup>

Address:

<sup>1</sup>Mother and Child Health Research, La Trobe University, 324-328 Little Lonsdale St, Melbourne, Victoria 3000, Australia.

<sup>2</sup>Menzies Research Institute, University of Tasmania, Private Bag 23 Hobart, Tasmania 7001, Australia.

<sup>3</sup>Department of Health Social Science, School of Public Health and Preventive Medicine, Monash University, Caulfield East VIC 3145, Australia.

<sup>4</sup>Department of Endocrinology and Diabetes and Centre for Hormone Research, Royal Children's Hospital and Murdoch Childrens Research Institute, Flemington Rd, Parkville, Victoria 3052, Australia.

.

Email:

Fiona Bruinsma – [f.bruinsma@latrobe.edu.edu](mailto:f.bruinsma@latrobe.edu.edu)

Jo-Anne Rayner - [j.rayner@latrobe.edu.au](mailto:j.rayner@latrobe.edu.au);

Alison Venn – [Alison.venn@utas.edu.au](mailto:Alison.venn@utas.edu.au)

Priscilla Pyett - [priscilla.pyett@monash.edu.au](mailto:priscilla.pyett@monash.edu.au)

George Werther - [george.werther@rch.org.au](mailto:george.werther@rch.org.au)

\*Corresponding author

## **Abstract**

### ***Objective:***

Public health research is an endeavour that often involves multiple relationships, far-reaching collaborations, divergent expectations and various outcomes. Using the Tall Girls Study as a case study, this paper will present and discuss a number of methodological, ethical and legal challenges that have implications for other public health research.

### **Approach:**

The Tall Girls Study was the first study to examine the long-term health and psychosocial effects of oestrogen treatment for tall stature.

### **Results:**

In undertaking this study the research team overcame many hurdles: in maintaining collaboration with treating clinicians and with the women they had treated as girls - groups with opposing points of view and different expectations; using private practice medical records to trace women who had been patients up to forty years earlier; and exploring potential legal issues arising from the collection of data related to treatment.

### **Conclusion:**

While faced with complex challenges, the Tall Girls Study demonstrated that forward planning, ongoing dialogue between all stakeholders, transparency of processes, and the strict adherence to group-developed protocols were keys to maintaining rigour while undertaking pragmatic research.

**Implications:**

Public health research often occurs within political and social contexts that need to be considered in the planning and conduct of studies. The quality and acceptability of research findings is enhanced when stakeholders are engaged in all aspects of the research process.

## **Introduction**

Public health research often involves investigation of topics that are broad and complex and generates findings with social as well as health implications. This paper tells the story of the Tall Girls Study and uses it as a case study to consider issues that may arise in other public health research. The paper begins with the background to the Tall Girls Study. It then discusses aspects of study design, particularly in regard to accessing an appropriate cohort, tracing study participants and practicalities of data collection. Ethical issues and consumer participation are also discussed.

The first long-term follow-up of girls treated with oestrogens, the Tall Girls Study, was undertaken in Australia between 2000 and 2003 [1]. The study examined a broad range of health and psychosocial outcomes in women treated with high dose oestrogens as adolescents in an attempt to reduce their adult height and compared them with women who were assessed but not treated for tall stature. While the short-term side-effects of this treatment, including weight gain, menstrual irregularities, nausea, night cramps and limb pains, benign breast disease, excessive vaginal discharge, thrombosis and ovarian cysts were well documented [2-5], nothing was known about the long-term health and psychosocial outcomes of this treatment. The study contributed to a broader understanding of the associations of high levels of oestrogen in adolescence on reproductive [1] and other outcomes [6-9].

## **Background**

Very little information is available on the evolution of the use of high dose oestrogens as a treatment for tall stature in healthy adolescents. After the successful use of this treatment in children with pituitary gigantism in the 1940s [10], clinicians in the

United States (US) extended the treatment to tall girls with concerns about their height but who had no associated pathology [3]. The first report of treatment of tall girls was published in 1956 [11]. There have been no randomised controlled trials of treatment effectiveness, and cohort studies have demonstrated that treatment is only moderately effective [9]. Despite this, the treatment became an accepted clinical practice in many countries including Australia [12-13].

Treatment was based on the knowledge that normally in puberty oestrogen inhibits further increases in height by fusing the epiphyses (growth-plates) of the long bones. Most treating clinicians considered treatment acceptable if a girl's adult height was predicted to be above the 97<sup>th</sup> percentile or two standard deviations above the mean female adult height in the given population [2, 4]. Determination of predicted adult height involved estimating bone age after an x-ray of the hand and wrist and assessing the remaining growth potential [14-16]. The various methods for calculating predicted adult height are prone to error [17].

The earliest predicted height criterion for oestrogen treatment in the US was 173cm in 1956 [11, 18-19] and this gradually increased over time but continued to fluctuate between countries. During the 1970s, Australian girls with a predicted adult height of  $\geq 177$ cm were eligible for treatment [2]; in the US, girls whose predicted adult height was above 173cm [20] or 182.9cm [21] were also treated; and in Germany and the Netherlands the treatment criterion was a predicted height of  $\geq 180$ cm [22-23]. Age at initiation and duration of treatment also varied considerably and was strongly associated with overall treatment effectiveness. The clinical challenge was that the accuracy of predicting adult height increased after the age of ten years (or closer to

puberty) however the potential height reduction diminished [24]. Some clinicians waited until girls grew to an arbitrary height before initiating treatment: 167cm in Australia [2]; 169.5cm in the US [24]; and 170cm in Europe [25]; while others waited until girls reached puberty when they were more likely to be psychologically ready for the effects of treatment on their development but when treatment may be less effective [26]. Duration of treatment varied but was generally two to four years [2, 23, 27]. Treatment regimes varied considerably and initially were a combination of oestrogen and testosterone [11]. Various preparations of oral synthetic [2, 23, 28] or conjugated oestrogens [25] were given continuously or cyclically; oestrogen pellets were inserted under the skin at six monthly intervals [29] for some; and intramuscular injections of oestrogen were given to others [24, 26, 30-31].

The rationale for treatment was to reduce perceived psychosocial 'risks' tall girls may face in adulthood. These included physical deformity, through tall girls' adoption of slouching in an effort to reduce their height; and psychological distress and social withdrawal as a consequence of tall girls' difficulty conforming to cultural stereotypes [2-3, 18, 24, 32-33]. However, there was very little reporting of any evidence for these assumptions [13] and there are very few published studies reporting psychosocial outcomes following treatment. Three relevant studies [33-35] were limited by small samples sizes, the participants being still relatively young, and the fact that the investigators were treating clinicians which may have affected responses. While treatment is relatively uncommon now in Australia, it was still being used in the US in 2002 [36]; is currently recommended for the management of familial tall stature [37]; and more controversially has been proposed as a form of clinical

management of disabled children to reduce their height and increase manageability [38].

The use of synthetic oestrogens as a medical treatment to reduce the height of tall girls was relatively unknown among the general public during the decades it was at its peak in Australia and elsewhere. Even within some families a girl's height assessment and treatment was kept a secret from other family members.

Public awareness of the treatment of tall girls came about in Australia in 1997, when the treatment became part of a wider debate in the Australian Federal Parliament on the use of human biological products and post-war medical experimentation [39]. Subsequent to the media coverage of this issue, the need for a comprehensive follow-up study was raised independently both by Australian endocrinologists and by women who had been assessed and treated for tall stature as adolescents. These women formed a lobby group, Tall Girls Inc., to petition the government for a follow-up study citing a range of health concerns and that their families had been unaware of the experimental nature of this treatment [40].

Clinicians and Tall Girls Inc. alike had concerns about the possibility of long-term effects of oestrogen treatment, particularly exposure to diethylstilboestrol (DES), which is associated with serious adverse outcomes when given to pregnant women [41-42].

In early 1998, the paediatric endocrinology group at the Royal Children's Hospital was under increasing pressure to conduct a follow-up study to examine long-term

outcomes of treatment and was looking for a group of researchers with whom to collaborate. Researchers at La Trobe University who were interested in the research and had significant experience in conducting long-term follow-up studies in women's health met with treating clinicians. Following an agreement for the need for a study and for formal collaboration, a period of intense discussion and consultation was undertaken with all parties to formulate the study design and research questions. Given their investment in the project and the sense of disenfranchisement that many treated tall girls felt from the original decision-making, Tall Girls Inc. and particularly the president, Janet Cregan-Wood, were involved from inception in the study design process.

In 2000, the National Health and Medical Research Council (NHMRC) provided funding for a follow-up study - The Tall Girls Study. The funding proposal submitted to NHMRC was a joint venture between the research team at La Trobe University, Tall Girls Inc. and a paediatric endocrinologist who was familiar with the treatment approaches to tall stature, and who facilitated access to the private practice medical records of a senior colleague who had treated the largest number of tall girls in Australia.

### ***Study design***

The study was, by necessity, designed as a retrospective cohort study. Ideally, the cohort would be comprised of all Australian women assessed for tall stature. However, the number of women who were assessed and/or treated in Australia was not known. What was known was that the private practice of one paediatric endocrinologist comprised a high proportion of treated tall girls. Meticulous records

had been kept and the specialist was willing to make them available for the study. In addition, a large number of women had been assessed for treatment as adolescents but their estimated adult height did not warrant treatment or their parents elected not to have the treatment. All treated and untreated (assessed only) women were considered eligible to participate and the inclusion of untreated women provided an important comparison group of tall women who had been through similar referral pathways.

To ensure the most complete coverage possible, a number of direct and indirect strategies were used to maximise recruitment. These included having access to the private medical records of the main treating clinician so we could trace women through public records and invite them to participate in the study; having access to the mailing list of Tall Girls Inc. so we could invite women directly; advertising the study through the mailing list of a tall women's clothing company; inviting other paediatric endocrinologists who may have treated tall girls to participate; and advertising through professional medical, nursing and ancillary associations and the alumni newsletters of private girls' schools. Some tall girls were referred for a height assessment by doctors and nurses undertaking yearly health checks in private girls' schools.

While these strategies increased the opportunity for women to self-refer into the study, reliance on these as the only recruitment method would have resulted in a study sample that was too small and findings prone to selection bias [43] if volunteers over-represented women reporting adverse outcomes.

The issues that we encountered were very similar (on a smaller scale) to those encountered by researchers aiming to investigate the health outcomes for women and their offspring who were administered diethylstilbestrol (DES) during pregnancy or were exposed in-utero [44], in that it was impossible to enumerate the total exposed cohort, accessing medical records posed a number of challenges and it was difficult to trace women over a long period of time.

### ***Clinical collaboration***

In Australia, the medical records of private medical practitioners are the property of the medical practitioner, not the individual to whom the record refers. Under both the Privacy Act 1988 (Commonwealth) and the Health Records Act 2001(Victoria), records cannot be divulged to a third party without the individual's consent, although there are some exemptions, one of which is where the research is in the public interest. It is a well accepted practice that health providers will contact patients on behalf of researchers to invite them to participate in relevant research. If the individual agrees, contact then happens directly between the participant and the research team. In Australia, private practitioners are not obliged to keep records of children once they reach 25 years of age or seven years after last contact.

While these provisions were designed to protect privacy and trust in the doctor-patient relationship there is also the possibility of gate-keeping by clinicians, where-by a clinician decides that the research is not appropriate, that the patient would not be interested or that participation would not be in the patient's best interests. This issue requires further ethical consideration as it removes choice from the individual and in some instances may protect the interests of those who are the gate-keepers.

These provisions have implications for investigating and reporting the long-term safety and outcomes of treatment. In the Tall Girls Study, we ascertained through Tall Girls Inc and the Australian Endocrinology Society that at least 51 other Australian doctors provided treatment. The research team traced and sought assistance from 35 doctors (16 were either in nursing homes or deceased) to determine whether they had treated tall girls, still had the girls' medical records and would be willing to recruit these women to the Tall Girls Study. Thirty-two doctors responded to the request: seven were willing to assist and could identify up to 100 eligible women; eight doctors had retained their medical records but could not readily identify those of tall girls; 12 doctors treated women but their records had been destroyed or were no longer in their possession; two doctors were unwilling to recruit women; and three had no recollection of having treated or assessed girls. Researchers investigating outcomes following use of DES faced similar challenges, with records destroyed, ineligible records or physicians being unwilling to participate [44].

In the case of the Tall Girls study, agreement was made between the private medical practitioners and the research team that the medical practitioners would release a small amount of information to researchers for tracing purposes (with no medical or treatment details) with appropriate human ethics committee approval. Once a current address was obtained, the medical practitioner would contact women on the researchers' behalf. During the tracing phase of the study, the specialist with the largest number of records died, however his family, in-line with his wishes, allowed the project to continue. Ethical approval was obtained for a modification to the approach in that the letter was sent by the researchers outlining how the woman's

details had been obtained. While this meant that we were directly contacting women (a small number of whom were uncomfortable about this), it also had benefits. Some women were angry about their treatment and may not have responded to an approach directly from their doctor. The research team took particular care to emphasise that while collaborating with, and in contact with both clinicians and Tall Girls Inc., the research was conducted by an independent research team.

### ***Tracing and recruitment***

One of the greatest challenges the study faced was tracing women between 14 and 40 years after they were assessed or treated for tall stature. Much of the information from medical records was out of date, as parents were unlikely to still be living at the same address and most women would have changed their surname with marriage. Despite assistance from the Australian Electoral Commission (AEC), who performed record linkage on name and date of birth, tracing women using the medical record data to try and link names and addresses over time involved tedious and time-consuming trawling through years of public records including electoral rolls, telephone books and death notices, all on microfiche. The National Death Index (NDI) was also used to record link registered Australian deaths with the names and dates of birth of women. Tracing and contacting women to invite them into the study was crucial to help minimise selection bias and to build confidence in the study findings. Considerable effort was made to locating women who may have changed their name.

Once again, this experience had many parallels with the experience and strategies used in the Diethylstilbestrol-Adenosis (DESAD) project conducted by Nash and colleagues[44]. We were able to trace 87% of women identified as eligible from

medical records[1], a great result given the limited information available and the duration of time to follow-up. The effectiveness of different strategies will vary greatly between countries; it is important to tailor strategies according to local circumstances to obtain optimal results. For instance, in Australia, voting is compulsory so use of the electoral roll provides good population coverage, where voting is not compulsory this will not be the case.

In all instances it is vital for rigorous epidemiological research that access to sources for tracing be maintained. Privacy is important; however this must be balanced with the public expectation that information is available on the long-term impact and effects of medical treatments. Studies would be unable to be conducted, or the validity of which would be compromised, if access to named or identifying data on a population-based level was not possible.

An additional issue was the gate-keeping by parents of adult children. In some instances we were able to trace parents but not the children. In these instances we contacted the parents and asked them for contact details of their daughter(s) or requested that they forward to them our letter of invitation. Some parents were reticent or refused to do this as they felt it would re-open old wounds. In these instances we tried to collect limited data from the parents on their daughter's health and relationship status.

The issues outlined in the previous two sections, namely storage and retrieval of medical records, availability of records and willingness of practitioners to participate, tracing and recruitment of participants, have ongoing implications for public health

research. Each year new treatments and new medications are added to standard clinical practice, the long-term implications of which cannot always be foreseen [44]. An interesting example, with some parallels to the treatment of tall girls, is the current use of hormone treatments for short stature [45]. Another example is the potential need to trace women administered human pituitary growth hormone (hGH) [46] and human pituitary gonadotrophin [47]. Tracing plays an important part in accurately reporting outcomes and reducing bias in findings. It requires access to population-based identifying data sources or use of a unique identifying number. However, prior to this, accurate records of treatment must be kept.

#### **Practicalities of data collection**

The Tall Girls Study collected data on multiple health and psychosocial outcomes. This necessitated a range of quantitative and qualitative methods each of which had specific challenges. The primary exposure of interest was the synthetic oestrogens used to accelerate puberty and retard growth (height) which would be ascertained through access to medical record data. A postal questionnaire collected self-reported information on current health status using standard validated tools, treatment history, family attitudes to tall stature, perceived advantages and disadvantages to tall stature and satisfaction with treatment using structured and open-ended questions; and personal and demographic details including current height. Information considered more complex or sensitive including reproductive and sexual history and mental health status was collected using a computer assisted telephone interview (CATI). This study design allowed women to consent to participate in all components of data collection (medical records data abstraction, postal survey, CATI) or as many as they felt comfortable with.

Due to the number of telephone interviews that needed to be conducted over a relatively short period of time and the difficulties in staffing and scheduling these, it was decided to contract these interviews to a commercial interviewing company. Once interviewing commenced it became clear that the interviewers had very little experience in health, they did not tailor contact to the times that women had already indicated were convenient and although initially they had indicated that they were happy for the project manager to be on site and monitor some of the interviews, in practice this was not the case. The interviews were significantly more complex and took significantly longer than they had estimated in their costing (despite a number of briefings). The commercial company only completed half of the CATI interviews.

The remaining interviews were conducted in-house by the project manager and two members of the project team. This change meant that any queries about the study or associated issues regarding being an assessed or treated tall girl could be clearly and accurately addressed. An additional advantage of the project team being involved in data collection was that it gave a good sense of the strengths and weaknesses of data items which then informed the analysis process. While conducting the interviews in-house had advantages, it also had costs (both economic and emotional). A small number of CATIs needed to be conducted with women who were living overseas and it required rescheduling of staff work hours as a high proportion of interviews needed to be conducted between 5 and 9pm at night and in some instances in the early hours of the morning. Some of these interviews were also emotionally taxing and the three in-house interviewers conducted approximately 100 interviews each over the space of a few months. Regular debriefing was required; this was conducted by other team

members. For some participants this was the first time they had discussed their experience of assessment or treatment with anybody and even though this wasn't part of the CATI they would want to share this as well as sometimes seeking information about why certain examinations/tests were done.

This experience illustrates the need for experienced research staff to conduct interviews that are of a sensitive and complex nature. This is important both for ensuring the quality and accuracy of the data collected but also in terms of providing a positive experience of research for participants. The need for staff training and debriefing should not be overlooked.

### **Ethical issues**

The use of information from private medical records without individual consent for the purposes of research raises important legal and ethics issues [43, 48]. As has already been mentioned the study required access to medical records held by private medical practitioners. The research team needed to balance obtaining data on long-term outcomes with not harming participants. For some women, the study brought back difficult memories and raised a topic that had previously been taboo within the family. The research team put together detailed protocols regarding these issues. A small number of women (less than five) were concerned about how their details were obtained and these were immediately reported to the ethics committee and were successfully resolved.

A more contentious issue was access to medical records. Some women had been trying unsuccessfully to access their medical record via the private practitioner and there was previous (and current at the time the study began) legal action between a

small number of women and one medical practitioner. At the beginning of the study the research team investigated whether study data could be subpoenaed in litigation or whether data collected for the study could be accessed via a Freedom of Information request. Examination of Victorian freedom of information legislation suggested that it may be possible but legal advice indicated that a request for an exemption could be made given that such a precedent may jeopardise research more generally.

The knowledge that we were able to access the records for research purposes prompted some women to ask us to provide them with the information. Many women could not remember what treatment they had received and were eager to know. This placed the research team in an unusual and difficult position: we had obligations to the medical practitioners who were assisting us with our research, and to study participants [43]. After discussion with representatives of the primary medical practitioner concerned, and after legal advice and in line with the health privacy principles of the Victorian Health Records Act (2001), we developed a policy where women could be provided with a summary of the data that was abstracted from the medical record and also a summary of the data collected using the study instruments. If the woman wanted to see the medical record or obtain copies of photos or other original material she needed to contact the representative of the relevant medical practitioner. In practice, less than 10 women requested access to their study records.

### **Consumer collaboration**

The involvement of Tall Girls Inc. was crucial for a number of reasons. One reason why the study was being conducted was to address their concerns about the possible adverse outcomes of treatment. Their support of the study was vital in terms of

encouraging women to participate and promoting the study through their networks and the media. The topic was particularly emotive for this group of women. However, as any one study is unable to answer all research questions, the research team felt the participation of Tall Girls Inc. in the research design process from the beginning to be important. This involved numerous and lengthy discussions about what the project could and could not do, as well as their input into study questions. While time-consuming, we believe that this investment of time and genuine involvement in the research process had dividends for both the research team and members of Tall Girls Inc. It ensured that the study questions were relevant. At the end of the study the group had more realistic expectations about the findings and accepted them more readily. Their involvement in the process was felt to be empowering. While the involvement of consumers and clinicians was important, the study was conducted independently of both stakeholder groups. Public health investigation intersects frequently with the community and community advocacy groups; a particular example is the investigation of cancer clusters. Very few cancer clusters are found to be attributable to a particular cause or exposure but frequently the findings are received with scepticism. The experience of active engagement and explanation of research process and design may assist in this understanding.

### **Implications**

This paper has provided the social and historical context of a retrospective cohort study. Our experience with undertaking this study has implications for wider public health research. We believe active engagement with stakeholders provided a positive experience of the research process, improved the design of the study instruments and facilitated acceptance and understanding of the study findings. It also highlights the need for accurate record-keeping and systematic storage of records over an extended

period of time and for access to records that allow tracing to take place. Further clarification of ethical and legal access to records would facilitate studies investigating long-term outcomes of interventions and treatments

### **Competing Interests**

The authors declare that they have no competing interests.

### **Authors' information**

AV, GW and PP were responsible for the design, conduct and interpretation of the Tall Girls Study. FB, JR and AV contributed to the design and interpretation of the original study and the conception and writing of the paper.

### **Acknowledgements and funding**

We thank the women who participated in the study, members of Tall Girls Inc, and the physicians who provided access to their medical records. A special thank you to Professor Judith Lumley for her part in the inception of the study and continued involvement and support throughout and for Penelope Jones for research assistance. The study (the Tall Girls Study) on which this paper is based was supported by a grant from the National Health & Medical Research Council. During the writing of this paper FB and JR were supported by a National Health and Medical Research Council Capacity Building Grant in Population Health Research. NHMRC ID: 433043.

### **References**

1. Venn A, Bruinsma F, Werther G, Pyett P, Baird D, Jones P, Rayner J, Lumley J: **Oestrogen treatment to reduce the adult height of tall girls: long-term effects on fertility.** *Lancet* 2004, **364**:1513-1518.
2. Wettenhall H, Cahill C, Roche A: **Tall girls: A survey of 15 years of management and treatment.** *J Pediatr* 1975, **86**(4):602-610.
3. Crawford J: **Treatment of tall girls with estrogen.** *Pediatr* 1978, **62**(6 Supplement):1189-1195.

4. Drop S, de Waal W, de Moinck Keizer-Schrama S: **Sex steroid treatment of constitutionally tall stature.** *Endocrinol Rev* 1998, **19**(5):540-558.
5. Trygstad O: **Oestrogen treatment of adolescent tall girls: Short term side effects.** *Acta Endocrinol* 1986, **279**:170-173.
6. Bruinsma F, Venn A, Patton G, Rayner J-A, Pyett P, Werther G, Jones P, Lumley J: **Concern about tall stature during adolescence and depression in later life.** *J Affect Disord* 2006, **91**:145-152.
7. Pyett P, Rayner J, Venn A, Bruinsma F, Werther G, Lumley J: **Using hormone treatment to reduce the adult height of tall girls: Are women satisfied with the decision in later life?** *Soc Sci Med* 2005, **61**:1629-1639.
8. Jordan H, Bruinsma F, Thomson R, Amir L, Werther G, Venn A: **Adolescent exposure to high-dose estrogen and subsequent effects on lactation.** *Reprod Toxicol* 2007, **24**:397-402.
9. Venn A, Hosmer T, Hosmer D, Bruinsma F, Jones P, Lumley J, Pyett P, Rayner J, Werther G: **Oestrogen treatment of tall stature in girls: estimating the effect on height and error in height prediction.** *Clin Endocrinol* 2008, **68**(6):926-929.
10. Albright F, Reifenstein EJ, Forbes A, et al: **Effect of estrogen in acromegaly.** In: *Conference on metabolic aspects of convalescence, Transcriptions of 14th meeting of Josiah Macy Jr Foundation: New York: Josiah Macy Jr Foundation; 1946: 102.*
11. Goldzieher M: **Treatment of excessive growth in the adolescent female.** *J Clinical Endocrinol Metabol* 1956, **16**(2):249-252.
12. Rayner J, Pyett P, Astbury J: **The medicalisation of 'tall' girls: A discourse analysis of medical literature on the use of synthetic oestrogen to reduce female height.** *Soc Sci Med* 2010, **71**:1076-1083.
13. Cohen S, Cosgrove C: **Normal at any cost : tall girls, short boys, and the medical industry's quest to manipulate height.** New York: Jeremy P. Tarcher/Penguin; 2009.
14. Bayley N, Pinneau S: **Tables for predicting adult height from skeletal age: revised for use with the Greulich-Pyle hand standards.** *J Pediatr* 1952, **40**:423.
15. Tanner J: **Growth at adolescence: with a general consideration of the effect of heredity and environment factors upon growth and maturation from birth to maturity,** 2nd edn. Oxford: Blackwell Scientific Publications; 1962.
16. Tanner J, Whitehouse R: **Clinical longitudinal standards for height, weight, height velocity, weight velocity, and stages of puberty.** *Arch Dis Child* 1976, **51**(3):170-179.
17. Joss E, Temperli R, Mullis P: **Adult height in constitutionally tall stature: accuracy of five different height prediction models.** *Arch Dis Child* 1992, **67**:1357-1362.
18. Freed S: **Suppression of growth in excessively tall girls.** *JAMA* 1958, **166**(11):1322-1323.
19. Bayley N, Gordan G, Bayer L, Goldberg M, Stormont A: **Attempt to suppress excessive growth in girls by estrogen treatment: statistical evaluation.** *J Clin Endocrinol Metabol* 1962, **22**:1127-1129.
20. Conte F, Grumbach M: **Epidemiological aspects of estrogen use: estrogen use in children and adolescents: a survey.** *J Pediatr* 1978, **62**:1091-1097.
21. Schoen E, Solomon I, Warner O, Wingerd J: **Estrogen treatment of tall girls.** *Am J Dis Child* 1973, **125**:71-74.

22. Bierich J, Schonberg D: **Hormonal treatment of familial tall stature.** *Acta Paed Scand* 1973, **62**:90-91.
23. de Waal W, Torn M, de Moinck Keizer-Schrama S, Aarsen R, Drop S: **Long term sequelae of sex steroid treatment in the management of constitutionally tall stature.** *Arch Dis Child* 1995, **73**(4):311-315.
24. Bailey J, Park E, Cowell C: **Estrogen treatment of girls with constitutional tall stature.** *Pediatr Clin North Amer* 1981, **28**(2):501-512.
25. Bierich J: **Estrogen treatment of girls with constitutional tall stature.** *Pediatr* 1978, **62**(6 Supplement):1196-1121.
26. Prader A, Zachmann M: **Treatment of excessively tall girls and boys with sex hormones.** *Pediatr* 1978, **62**(6 Suppl):1202-1210.
27. Prader A, Zachmann M, Murset G, Ferrandez A, Bambach M: **Treatment of excessively tall stature in children (girls and boys).** *Acta Paed Scand* 1973, **62**:89-90.
28. Normann E, Trygstad O, Larsen S, Dahl-Jorgensen K: **Height reduction in 539 tall girls treated with three different doses of ethinyloestradiol.** *Arch Dis Child* 1991, **66**(11):1275-1278.
29. Greenblatt R, McDonough P, Mahesh V: **Estrogen therapy in inhibition of growth.** *J Clin Endocrinol Metabol* 1966, **26**:1185-1191.
30. Whitelaw M: **Experiences in treating excessive height in girls with cyclic oestradiol valerate.** *Acta Endocrinol* 1967, **54**:473-484.
31. Andersen H, Jacobsen B, Kastrup K, Krabbe S, Peitersen B, Petersen K, Thamdrup E, Wichmann R: **Treatment of girls with excessive height prediction. Follow-up of forty girls treated with intramuscular estradiol and progesterone.** *Acta Paed Scand* 1980, **69**(3):293-297.
32. Kuhn N, Blunck W, Stahnke N, Wiebel J, Willig R: **Estrogen treatment in tall girls.** *Acta Paed Scand* 1977, **66**(2):161-167.
33. Binder G, Grauer M, Wehner A, Wehner F, Ranke M: **Outcome in tall stature. Final height and psychological aspects in 220 patients with and without treatment.** *Europ J Endocrinol* 1997, **156**:905-910.
34. de Waal W, Janssen A, van Bussbach J, de Muinck Keizer-Schrama S, Aarsen R, Slijper F, Drop S: **Chapter 8: Psychosocial aspects in constitutionally tall stature.** *PhD.* Rotterdam: Erasmus University; 1996.
35. Lecointre C, Toublanc J: **Psychological indications for treatment of tall stature in adolescent girls.** *J Pediatr Endocrinol Metabol* 1997, **10**:529-531.
36. Barnard N, Scialli A, Bobela S: **The current use of estrogens for growth-suppressant therapy in adolescent girls.** *J Pediatr Adolesc Gynecol* 2002, **15**:23-26.
37. Moon R, Davies J: **Evaluation of tall stature.** *Paediatr Child Health* 2010, **20**(1):43-45.
38. Gunther D, Diekema D: **Attenuating growth in children with profound developmental disability.** *Arch Pediat Adolesc Med* 2006, **160**:1013-1017.
39. Hughes G, Ryle G: **Hormone tests on teenage girls referred to inquiry.** In: *The Age.* Melbourne; 1997: 1-2.
40. Jennings G: **Tall girls.** In: *Afternoon with Gael Jennings.* Melbourne, Australia: 3LO, ABC Radio; 1997.
41. Giusti R, Iwamoto K, Hatch E: **Diethylstilbestrol revisited: a review of the long-term health effects.** *Ann Int Med* 1995, **122**(10):778-788.

42. Herbst A, Ulfelder H, Poskanzer D: **Adenocarcinoma of the vagina: association of maternal stilbestrol therapy with tumor appearance in young women** *N Eng J Med* 1971, **284**:871-881.
43. Venn A: **Using medical records in epidemiological research.** *Arch Manusc* 2003, **31**(2):51-59.
44. Nash S, Tilley B, Kurland L, Gundersen J, Barnes A, Labarthe D, Donohew P, Kovacs L: **Identifying and tracing a population at risk: The DESAD project experience.** *Am J Pub Health* 1983, **73**(3):253-259.
45. Bryant J, Baxter L, Cave C, Milne R: **Recombinant growth hormone for idiopathic short stature in children and adolescents.** *Cochrane Database of Systematic Reviews* 2007, **3**(CD004440):DOI: 10.1002/14651858.CD14004440.pub14651852.
46. Mills J, Fradkin J, Schonberger L, Gunn W, Thomson R, Piper J, Wysowski D, Brown P: **Status report on the U.S. Human Growth Hormone Recipient Follow-up Study.** *Hormone Res* 1990, **33**(2-4):116-120.
47. Allars M: **Report of the Inquiry into the Use of Pituitary Derived Hormones in Australia and Creutzfeldt-Jakob Disease.** Canberra; Australian Government Publishing Service 1994.
48. Bruinsma F, Venn A, Skene L: **Accessing patient's records without individual consent for epidemiological research.** *J Law Med* 2000, **8**:76-80.